A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1)
analogue that created on the basis of the Exenatide and modified by polyethylene glycol
(PEG).
This study aims to evaluate the PK, PD and safety by 8-week continuous treatment of PEX168.